Gene Therapy Regenerates Protein Expression in Cone Photoreceptors in Rpe65R91W/R91W Mice
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Cone photoreceptors mediate visual acuity under daylight conditions, so loss of cone-mediated central vision of course dramatically affects the quality of life of patients suffering from retinal degeneration. Therefore, promoting cone survival has become the goal of many ocular therapies and defining the stage of degeneration that still allows cell rescue is of prime importance. Using the Rpe65(R91W/R91W) mouse, which carries a mutation in the Rpe65 gene leading to progressive photoreceptor degeneration in both patients and mice, we defined stages of retinal degeneration that still allow cone rescue. We evaluated the therapeutic window within which cones can be rescued, using a subretinal injection of a lentiviral vector driving expression of RPE65 in the Rpe65(R91W/R91W) mice. Surprisingly, when applied to adult mice (1 month) this treatment not only stalls or slows cone degeneration but, actually, induces cone-specific protein expression that was previously absent. Before the intervention only part of the cones (40% of the number found in wild-type animals) in the Rpe65(R91W/R91W) mice expressed cone transducin (GNAT2); this fraction increased to 64% after treatment. Correct S-opsin localization is also recovered in the transduced region. In consequence these results represent an extended therapeutic window compared to the Rpe65(-/-) mice, implying that patients suffering from missense mutations might also benefit from a prolonged therapeutic window. Moreover, cones are not only rescued during the course of the degeneration, but can actually recover their initial status, meaning that a proportion of altered cones in chromophore deficiency-related disease can be rehabilitated even though they are severely affected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Hattar, S., Lucas, R. J., Mrosovsky, N., Thompson, S., Douglas, R. H., Hankins, M. W., Lem, J., Biel, M., Hofmann, F., Foster, R. G., et al. (2003) · Nature · doi:10.1038/nature01761 · Cited by 1,245 · cited 1×
“photoreceptors are the source for a PLR mediated by short stimuli [41,42].”
BackgroundGene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
Morimura, H., Fishman, G. A., Grover, S. A., Fulton, A. B., Berson, E. L., & Dryja, T. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3088 · Cited by 481 · cited 1×
“The R91W mutation was described in patients suffering from an early-onset retinal degeneration [25], who experience useful cone-mediated vision in the first decade of life [26].”
BackgroundEffective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460 · cited 1×
“This effect is coherent with the improvement of scotopic ERG observed after gene transfer in adult Rpe65-deficient mice which are more severely affected than Rpe65 mice [9,11,13].”
ResultLeber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy
Cideciyan, A. V. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.002 · Cited by 256
Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog
Narfstro¨m, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A., Redmond, T. M., Caro, L., Lai, C.-M., & Rakoczy, P. E. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0595 · Cited by 252
Znoiko, S. L., Rohrer, B., Lu, K., Lohr, H. R., Crouch, R. K., & Ma, J.-X. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0653 · Cited by 146 · cited 3×
“From this point of view, Rpe65-deficient mice are interesting models to study cone degeneration, since in this case cone loss occurs before rod loss [6].”
BackgroundInfluentialCone Opsin Mislocalization in Rpe65−/−Mice: A Defect That Can Be Corrected by 11-cis Retinal
Rohrer, B., Lohr, H. R., Humphries, P., Redmond, T. M., Seeliger, M. W., & Crouch, R. K. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0533 · Cited by 133
Jin, M., Li, S., Nusinowitz, S., Lloyd, M., Hu, J., Radu, R. A., Bok, D., & Travis, G. H. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3882-08.2009 · Cited by 109
Zhang, H., Fan, J., Li, S., Karan, S., Rohrer, B., Palczewski, K., Frederick, J. M., Crouch, R. K., & Baehr, W. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0317-08.2008 · Cited by 101 · cited 2×
“The reason for cone death is not yet fully determined however there are now several reports suggesting that the lack of 11-cis-retinal is the main cause for cone degeneration in different mouse models (Lrat [30,31], Irbp [32]).”
BackgroundRpe65−/−and Lrat−/−Mice: Comparable Models of Leber Congenital Amaurosis
Fan, J., Rohrer, B., Frederick, J. M., Baehr, W., & Crouch, R. K. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-1727 · Cited by 95 · cited 2×
“The reason for cone death is not yet fully determined however there are now several reports suggesting that the lack of 11-cis-retinal is the main cause for cone degeneration in different mouse models (Lrat [30,31], Irbp [32]).”
BackgroundRPE65 Gene Delivery Restores Isomerohydrolase Activity and Prevents Early Cone Loss in Rpe65−/−Mice
Chen, Y., Moiseyev, G., Takahashi, Y., & Ma, J.-X. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0965 · Cited by 80
Caruso, R. C., Aleman, T. S., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Mullins, C. L., Boye, S. L., Hauswirth, W. W., & Jacobson, S. G. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5559 · Cited by 26 · cited 1×
“Rods degenerate more slowly, with residual function demonstrated up to 24 months [29].”
Background
Cited by
Cideciyan, A. V., Jacobson, S. G., Beltran, W. A., Sumaroka, A., Swider, M., Iwabe, S., Roman, A. J., Olivares, M. B., Schwartz, S. B., Komáromy, A. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218933110 · Cited by 444
Gene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
“In a mouse model of moderate RP, Rpe65, the loss of rod followed by cone photoreceptors is not as rapid as in other models (such as the rd10 mouse model), thus, allowing for investigation regarding how late into the disease progression cone rescue can still occur.(15) The results suggest that for RP cases resulting fr…”
Gene therapy for inherited retinal disease: Long-term durability of effect
Leroy, B. P., Fischer, M. D., Flannery, J. G., MacLaren, R. E., Dalkara, D., Scholl, H. P. N., Chung, D. C., Spera, C., Viriato, D., & Banhazi, J. (2023) · Ophthalmic Research · doi:10.1159/000526317 · Cited by 70
Lentiviral vectors for ocular gene therapy
Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081605 · Cited by 47
“In another mouse model of RPE65 deficiency in which the R91W missense mutation leads to a slow degeneration, gene augmentation was also efficient during the degenerative process [154].”
BackgroundSelf-citationMatet, A., Kostic, C., Bemelmans, A.-P., Moulin, A., Rosolen, S. G., Martin, S., Mavilio, F., Amirjanians, V., Stieger, K., Lorenz, B., et al. (2017) · Translational Research · doi:10.1016/j.trsl.2017.06.012 · Cited by 20
“For this study, we used the human RPE65 cDNA, while the mouse RPE65 cDNA was used previously to demonstrate vector efficacy in RPE65 mouse models.(30,31,35) The RPE65 LV (LV-RPE65) was produced by transient transfection of suspended HEK293 T cells in a serum-free media (customized F17 medium, Invitrogen, Carlsbad, Cal…”
MethodSelf-citation
Metadata
- Authors
- Kostic, C., Crippa, S. V., Pignat, V., Bemelmans, A.-P., Samardzija, M., Grimm, C., Wenzel, A., & Arsenijevic, Y.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-02-03
- Volume
- 6
- Issue
- 2
- Pages
- e16588
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2019718689
- Cited by
- 26
- References
- 18
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.